Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02917187 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
A Phase 2 study of Primary Inherited Erythromelalgia, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT02917187: Completed Phase 2 study of Primary Inherited Erythromelalgia, sponsored by Biogen.
NCT02917187 is a Phase 2 study of Primary Inherited Erythromelalgia that has completed, run by Biogen. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02917187, a Phase 2 study of Primary Inherited Erythromelalgia, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additional aspects of pain in participants with EM; and to investigate the safety and tolerability of repeat oral dosing of BIIB074 in participants with EM.
Primary Outcome
11-point Pain Intensity Numerical Rating Scale (PI-NRS) is used to assess EM paroxysmal pain. PI-NRS is an 11-point pain intensity numerical rating scale, where 0=no pain and 10=worst possible pain. Weekly average is defined as the total of severity scores during a week divided by the total number of paroxysms during that week.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BIIB074
Study Locations (5)
Alabama
- Research Site - Birmingham
Connecticut
- Research SIte - New London
Pennsylvania
- Research Site - Philadelphia
Texas
- Research Site - Plano
West Virginia
- Research Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2017-01-05 |
| Phase | Phase 2 |
What the finished NCT02917187 record still lists
NCT02917187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Primary Inherited Erythromelalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02917187 lists 5 locations in 5 states (Alabama, Connecticut, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02917187 about?
NCT02917187 is a clinical study titled "A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia". The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additiona...
What is the current status of trial NCT02917187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-09-09. Estimated completion is 2017-01-05.
What conditions does trial NCT02917187 study?
This clinical trial studies the following conditions: Primary Inherited Erythromelalgia.
What interventions are being tested in trial NCT02917187?
The interventions under investigation include: Placebo (DRUG), BIIB074 (DRUG).
Who is sponsoring clinical trial NCT02917187?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02917187 being conducted?
This trial has 5 study locations across Alabama, Connecticut, Pennsylvania, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02917187's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI